Adamas Pharmaceuticals Inc ADMS:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/04/21 EST
4.70quote price arrow down-0.43 (-8.38%)
Volume
1,467,293
52 week range
1.90 - 9.15

...

Loading . . .

KEY STATS

  • Open5.04
  • Day High5.12
  • Day Low4.38
  • Prev Close4.70
  • 52 Week High9.15
  • 52 Week High Date02/01/21
  • 52 Week Low1.90
  • 52 Week Low Date03/18/20
  • Market Cap194.44M
  • Shares Out41.37M
  • 10 Day Average Volume1.08M
  • Dividend-
  • Dividend Yield-
  • Beta2.69
  • 1 Year % Change12.04

RATIOS/PROFITABILITY

  • EPS (TTM)-2.03
  • P/E (TTM)-2.32
  • Fwd P/E (NTM)-2.59
  • EBITDA (MRQ)-43.313M
  • ROE (MRQ)-851.33%
  • Revenue (MRQ)74.46M
  • Gross Margin (MRQ)97.26%
  • Net Margin (MRQ)-77.09%
  • Debt To Equity (MRQ)-260.05%

EVENTS

  • Earnings Date05/07/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Adamas Pharmaceuticals Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and...
David Mahoney
Chairman
Neil McFarlane
Chief Executive Officer
Christopher Prentiss
Chief Financial Officer
Address
1900 Powell St Ste 1000
Emeryville, CA
94608-1839
United States